Full year and fourth quarter 2021 results announcement

Medicure Inc. announced full year and fourth quarter 2021 results for the year ended 31 December 2021 on Thursday 28 April.

Learn More

Medicure Launches E-Commerce Pharmacy Platform Through its Subsidiary Marley Drug Pharmacy

Medicure Inc.– via Marley Drug, creates a direct-to-consumer e-commerce pharmacy solution. The service is available in all 50 states and can fulfill a formulary of over 100 prescription medications.

Learn More

Medicure's subsidiary, Marley Drug, announces strategic partnership with RxSpark

Partnership will integrate Marley Drug as the sole mail-order pharmacy for the RxSpark platform allowing consumers using the platform to receive medication directly to their door.

Learn More

Research and Products

Phase 3 clinical trial evaluating MC-1 for treatment of pyridoxal 5'-phosphate-dependent epilepsy

Medicure has filed with the FDA an IND for the use of MC-1 as a novel treatment for seizures associated with pyridox(am)ine 5'-phosphate oxidase (PNPO) deficiency.

Learn More

Lipid management is important for heart health

At Medicure, we are focused on improving the heart health of patients by delivering safe and efficacious cardiovascular medicines and ensuring all patients get access to therapy.

Learn More

News and Media

Antiplatelet therapy in the management of stroke patients

Medicure Announces Early Completion of Enrollment for iSPASM, a Phase 1/2a Exploratory Clinical Trial in Patients with Aneurysmal Subarachnoid Hemorrhage

Learn More